Selected References
  • N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor, EORTC-NCI-AACR 2014 (Abs. 31).
  • Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure., BJU Int. 2013 Jan;111(1):44-52.
  • Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011;29: (Abs 4628).
  • Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). J Clin Oncol 2010; 28:15s, (Abs 5014).
  • Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). J Clin Oncol 2010;28, (Abs e13558).
  • Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors, Journal of Clinical Oncology 2009,27:30(5094-5101)
  • A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors., Clin Cancer Res.(2009) 15(21):6694-701
  • Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358, Cancer Research (2007) 67 (17):7987-90.
  • PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer, Mol Cancer Ther. 2007 6 (12):3158-68
  • 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem. 2006 Nov 30;49(24):7247-51.
Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.